FDA Proposes 503B Bulk-Compounding Exclusions for Semaglutide, Tirzepatide & Liraglutide

Verified May 8, 2026, Updated July 22, 2026: On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use based on clinical need. Public comment closed July 30, 2026 (extended from June 29 via Federal Register 2026-12937). If finalized, the clinical-need-list route would not authorize 503B bulk compounding of these substances; the separate shortage pathway is governed by its own statutory conditions. The proposal was not a final rule when last checked.

• •What changed: FDA proposed permanent 503B exclusion for semaglutide, tirzepatide, and liraglutide on April 30, 2026
• •Comment period: Closed July 30, 2026, extended from June 29 via Federal Register 2026-12937 (91 FR 38719, published June 26, 2026) under Docket FDA-2018-N-3240. Comments are no longer accepted; the notice remains readable at the Federal Register notice (the page has a 'Submit a Formal Comment' button that routes to the active regulations.gov docket).
• •Immediate patient impact: The proposal is not a final rule and does not itself decide whether an individual prescription complies with Sections 503A or 503B
• •If finalized: The 503B clinical-need bulks-list route would not cover these three substances
• •503A: Patient-specific compounding remains subject to all statutory conditions, including limits on products that are essentially copies of approved drugs
• •Compounded tirzepatide: FDA declared the shortage resolved in October 2024; current availability does not establish that a particular prescription or pharmacy complies with federal and state requirements

What the 503B Bulk List Is, and Why This Matters

503B outsourcing facilities are large-scale pharmaceutical manufacturers licensed by the FDA to compound drugs at commercial scale. Unlike 503A patient-specific pharmacies, which fill individual prescriptions one at a time, 503B facilities can produce bulk quantities for healthcare facilities and telehealth platforms. That production capacity is what powered the compounded GLP-1 boom from 2021 to 2025.

Section 503B provides separate routes tied to the FDA drug-shortage list and the 503B clinical-need bulks list. A substance being nominated is not enough; FDA must place it on the applicable list, and the outsourcing facility must satisfy the rest of Section 503B. The April proposal addresses the clinical-need list. It does not turn a proposal into a final ban or decide every patient-specific 503A prescription.

The FDA's stated rationale, per the Orrick regulatory analysis of the proposal: when manufacturers have proven they can maintain adequate supply, allowing large-scale 503B compounding of their products creates safety risks without the shortage benefit. Over 520 adverse event reports linked to compounded GLP-1 products, including contamination, dosing errors, and unapproved additives, are part of the agency's record supporting permanent exclusion.

How This Differs from the Current Semaglutide and Tirzepatide Enforcement

FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, then ended its temporary enforcement-discretion periods. The April 2026 proposal operates on a different 503B route: the clinical-need bulks list. Availability of a compounded product after a shortage ends does not, by itself, prove either compliance or illegality.

In practical terms, the resolved shortages ended the broad shortage-based enforcement discretion that fueled mass-market supply. The proposal would also close the 503B clinical-need-list route for these substances if finalized. Those are important constraints, but neither statement is a blanket adjudication of every compounded prescription.

The Fifth Circuit Affirmed Both Delistings, and Nothing You Can Buy Changed

The trade headlines on August 27, 2026 read like a new restriction landed. Read the opinions and it is the opposite: a challenge to a two-year-old status quo failed, and the status quo was already the thing governing your prescription. On that date the United States Court of Appeals for the Fifth Circuit issued two separate opinions in Outsourcing Facilities Association v. FDA and affirmed the district court in both. The disposition line is identical in each: 'For the foregoing reasons, we AFFIRM the district court's judgment.' We read both opinions in full rather than the coverage, because the two questions the panel answered are not the same question, and only one of them was decided on the merits.

The second question was reached on the merits. In both cases the panel held the FDA's shortage determination was not arbitrary or capricious under the Administrative Procedure Act, crediting the agency's decision to weigh manufacturer supply and demand data above the anecdotal access reports submitted by compounders, telehealth companies and individuals. That is a real merits holding about the delisting decisions themselves, and it is the part of these opinions that will be cited.

• •Court: United States Court of Appeals for the Fifth Circuit, decided August 27, 2026
• •Panel: Richman, Duncan and Oldham, Circuit Judges. Both opinions are per curiam and there is no dissent or concurrence in either
• •Precedential weight: neither is binding precedent. Each carries the footnote 'This opinion is not designated for publication. See 5th Cir. R. 47.5.' A footnote in No. 25-10758 refers to the companion case as a forthcoming F.4th citation, which the companion's own publication footnote contradicts
• •Nothing was remanded. Both judgments were affirmed outright, so no part of either case returns to the district court for further work
• •Not final yet. The Fifth Circuit's docket entry in No. 25-10600 sets the mandate issue date at October 19, 2026. Until the mandate issues the compounders can petition for panel or en banc rehearing, and can afterwards ask the Supreme Court to take the case, so anyone describing this as the end of the litigation is ahead of the record
• •Which delisting each case covered: No. 25-10600 covers the tirzepatide decision, which the FDA first made on October 2, 2024 and re-issued on December 19, 2024 after reconsidering. No. 25-10758 covers the semaglutide decision, memorialized in a Declaratory Order dated February 21, 2025

So what changes for a patient today? Nothing. Compounded semaglutide and tirzepatide came off the shortage pathway in 2024 and 2025, and the enforcement-discretion windows that followed closed in 2025. These decisions confirm that those removals stand; they do not impose a new limit, they do not shorten a deadline, and they do not make anything unlawful that was lawful on August 26. If you are on a compounded preparation today, the question that governs your access is unchanged and it is the one in the section above: which 503A or 503B condition does your specific prescription satisfy. The compounding industry's live route back had been a court order reversing the delistings and reopening the shortage pathway, and these panel decisions block it. They do not close it yet. The Fifth Circuit set the mandate issue date at October 19, 2026, so the judgment has not issued, and until it does the compounders can ask the panel or the full court to rehear the appeals and can then petition the Supreme Court.

Why Liraglutide Is Included in the Proposal

Liraglutide, the active ingredient in Victoza (type 2 diabetes) and Saxenda (weight loss), is an older GLP-1 that still carries active entries on the FDA drug shortage database. We re-checked the openFDA drug shortages endpoint on August 29, 2026 and it returned 11 liraglutide records, 9 of them status Current. The picture changed on August 25, 2026: Saxenda (NDC 0169-2800-15, NDA 206321) now carries a To Be Discontinued entry reading 'Product will be available until discontinuation in January 2027', and Novo Nordisk has published the same advance notice on its own patient and clinician sites. Only the Saxenda brand is affected. Both Victoza 6 mg/1 mL presentations (NDC 0169-4060-12 and 0169-4060-13) still read Current at Limited Availability with an estimated duration listed as TBD, the Hikma, Meitheal and Teva-distributed generics all read Available, with the Meitheal presentation that had been at Limited Availability (NDC 71288-563-85) revised to Available on August 27, 2026, and one Teva generic (ANDA214568) has been flagged To Be Discontinued since May 14, 2026. So the accurate picture is one brand ending, one brand constrained, and the generics available, which is not a molecule-wide withdrawal. Liraglutide does remain an open entry on the shortage list, and Current on these records describes that listing rather than the individual presentation, which is why a record can read Current and Available at the same time. Our Saxenda discontinuation and switching guide covers what that means for a patient currently on the drug. Including liraglutide in the permanent exclusion proposal signals the FDA is closing a potential substitution loophole: as semaglutide and tirzepatide compounding access narrows, some 503B facilities could shift production to liraglutide, which shares GLP-1 mechanisms and is technically similar to compound at scale. The proposal is written to apply regardless of drug shortage status, so these entries do not change what it would do.

Liraglutide produces 5-6% body weight loss versus 15-21% for tirzepatide and 15% for semaglutide, so it was not the primary driver of the compounded GLP-1 market. But the FDA is not leaving that gap open. Including liraglutide now prevents a second enforcement cycle later.

What Remains Legal: Your 503A Patient-Specific Options

The proposal addresses 503B outsourcing facilities, not Section 503A directly. A 503A pharmacy still has to satisfy every applicable federal and state condition. When a compounded product is essentially a copy of an approved drug, FDA guidance focuses on whether the prescriber documents a change that produces a significant difference for the identified patient. Examples are context, not an exhaustive safe harbor:

• •Patient-specific prescription, The pharmacy must compound for an identified patient under a valid prescription or applicable limited anticipatory-compounding rules
• •Significant difference when required, The prescriber should document the patient-specific change rather than relying on cost or a mass-market preference alone
• •All other conditions still apply, Ingredient eligibility, labeling, state pharmacy law, and the prohibition on essentially-copy compounding are separate requirements

The July 23-24 PCAC Peptide Vote: What the Committee Actually Recommended

There was a second compounding decision in the same window as the 503B comment deadline, and it has been almost entirely covered as a peptide story rather than a compounding story. On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee met at the White Oak campus to review seven peptides nominated for the 503A bulks list, the list that governs patient-specific compounding. This is the same regulatory machinery that decided the GLP-1 question, applied to the substances the peptide market moved into after the semaglutide and tirzepatide crackdowns.

The agenda splits across two days, and the Federal Register meeting notice names both the substances and the specific uses the FDA evaluated for each one. That second column matters more than the peptide names: the committee is not asked whether a peptide is interesting, it is asked whether there is a clinical need for compounding it for a stated use.

Note the one that overlaps our territory directly: MOTs-C was evaluated for obesity and osteoporosis. If you have been offered a peptide as a cheaper alternative to a GLP-1, this is the meeting that decides whether a compounding pharmacy can legally keep sourcing bulk material for it.

The market traded both days hard, which is worth knowing only because it tells you how much money is watching this list. Hims and Hers rose more than 10% intraday on July 23 after the BPC-157 vote landed, then gave most of it back to close up around 3% at $32.74. When emideltide became the first substance the panel turned down on July 24, the stock fell about 11%. Share prices are not evidence about a peptide, and they play no part in how we score or rank any provider. Vote tallies via STAT and the FDA advisory committee meeting page.

For your purposes as someone comparing weight-loss options, nothing legally changed on July 23. MOTs-C got a favorable committee recommendation for obesity, but a recommendation is not approval, the FDA has not acted, and the safety record below is exactly why the agency's own scientists advised against it. The proven, FDA-regulated weight-loss options are still the ones in our full provider rankings and our cheapest GLP-1 comparison. If you are researching these peptides in their own right rather than as a GLP-1 alternative, our sister site Best Peptide For That covers the vote and each peptide's evidence in depth.

Why the FDA Is Skeptical of Bulk Peptides: The Safety Record

The strongest argument against adding these peptides to the 503A list is not about the molecules. It is about what is actually in the vial. The supply chain feeding US compounders runs largely through foreign API manufacturers, and the FDA's own enforcement record from this year is unflattering.

• •A named manufacturer, in writing. On April 15, 2026 the FDA issued a warning letter to Hangzhou Yiqi Biotechnology, a registered API manufacturer in Zhejiang, China. The letter cites failure to perform process validation, failure to validate analytical test methods, and failure to run a stability program. Its blunt conclusion: the firm's APIs are 'adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act.'
• •Already blocked at the border. The same letter records that the FDA 'placed all drugs and drug products offered from your firm for import into the United States on Import Alert 66-40 on January 30, 2026,' three months before the warning letter itself was published. Enforcement here runs ahead of the paperwork the public can see.
• •Testing failure rates are not a rounding error. The Partnership for Safe Medicines, summarizing reporting on the bulk peptide market, cites a Texas testing lab finding that a third of peptide samples fail identity, purity, or quantity checks, and points to FDA adverse-event records including a life-threatening incident and a hospitalization linked to suspected contamination in BPC-157.

How to Submit a Public Comment Before July 30

The public comment period on the proposal closed July 30, 2026 (Docket FDA-2018-N-3240; extended from June 29 via Federal Register 2026-12937, 91 FR 38719, published June 26, 2026). Patients, prescribers, pharmacists, telehealth companies, and patient advocacy organizations were able to submit comments up to that date. The FDA reviews all substantive comments before issuing a final rule, and no final rule had been announced as of August 3, 2026.

• •Where to comment: the Federal Register notice 2026-08552, use the 'Submit a Formal Comment' button on that page, which routes to the active regulations.gov docket
• •What carries weight: Documented patient cases, clinical data, safety comparisons between 503B products and brand-name drugs, economic impact for patients who relied on compounded access
• •Who should comment: Patient advocacy groups, healthcare providers who prescribe compounded GLP-1s, pharmacy associations, and patients whose prescribers have documented a patient-specific clinical rationale
• •Deadline: July 30, 2026, extended from June 29, 2026 via Federal Register 2026-12937. Comments submitted after this date will not be considered in the final rule.

What This Means for Your GLP-1 Access Right Now

The proposal is not yet finalized. The comment period closed July 30, 2026 (Docket FDA-2018-N-3240; extended from June 29 via FR 2026-12937) and the proposal is now with the FDA for review, so a final rule could come at any point and none had been announced as of August 3, 2026. Your immediate access is governed by the current rules, not the proposed permanent ban. Here is where things stand by drug:

If you currently use compounded tirzepatide, do not infer legality from availability, a pharmacy license, or a provider's marketing. The shortage was resolved on October 2, 2024, and the shortage-based transition periods ended in early 2025. Ask the prescriber and dispensing pharmacy which 503A or 503B pathway and patient-specific rationale apply to your exact preparation, then verify the pharmacy record independently. Our provider pages report advertised prices and public records; they do not certify a prescription or batch as compliant.

If a prescriber recommends an FDA-approved alternative, NovoCare lists the Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and the oral pill from $149/mo, dose-dependent (verified August 7, 2026). LillyDirect lists Zepbound vials from $299/mo, while Sprout Health advertises $199 for the first month and $249/mo after for its telehealth program. Foundayo (orforglipron) starts at $149/mo; see all FDA-approved oral GLP-1 pills compared. For the regulatory switch context, see the post-shortage semaglutide guide.

Frequently Asked Questions

Does this proposal affect my current compounded tirzepatide prescription? Not by itself today. FDA resolved the tirzepatide shortage on October 2, 2024 and ended shortage-based enforcement discretion in early 2025. A current preparation must satisfy whichever 503A or 503B and state-law conditions actually apply; it should not be assumed to fall under 503A. The pending proposal concerns the separate 503B bulk-substances pathway and would matter only if finalized. Check our FDA safety alerts for sourced updates.

Can my doctor still prescribe compounded semaglutide under 503A? Not automatically. Shortage-based enforcement discretion ended in 2025, so a current preparation must independently satisfy every applicable 503A and state-law condition; a documented allergy, dose rationale, prescription, or advertised availability alone does not establish compliance. The pending 503B proposal concerns a separate pathway and is not a final blanket ruling on 503A prescriptions.

Is there any scenario where 503B compounding of semaglutide could restart under the current rules? Yes, technically, if semaglutide went back on the FDA shortage list. That is exactly the loophole the permanent exclusion proposal is designed to close. If finalized, no future shortage declaration would reopen 503B compounding for these three drugs.

Why is liraglutide in the proposal if almost no one is using it for weight loss? The FDA is preventing a substitution market from forming. As semaglutide and tirzepatide 503B access closes, facilities could pivot to liraglutide compounding. Including it now avoids a second enforcement cycle.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical or legal advice. GLP-1 medications require a prescription from a licensed healthcare provider. Consult your prescriber before making any changes to your medication regimen. Regulatory status reflects information available as of May 8, 2026 and is subject to change.

Sources